Matthew S Painter, DO | |
510 W 1st Ave, Toppenish, WA 98948-1564 | |
(509) 865-5600 | |
Not Available |
Full Name | Matthew S Painter |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 21 Years |
Location | 510 W 1st Ave, Toppenish, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1790724987 | NPI | - | NPPES |
388111 | Other | WA | DEPT OF LABOR & INDUSTRIES |
2096906 | Medicaid | WA | |
OP60795343 | Other | WA | DOH LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | OP60795343 (Washington) | Secondary |
207Q00000X | Family Medicine | OP60795343 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Othello Community Hospital | Othello, WA | Hospital |
Kadlec Regional Medical Center | Richland, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Columbia Basin Health Association | 4486564309 | 33 |
News Archive
The U.S. Department of Justice, on behalf of the U.S. Food and Drug Administration, has filed a complaint for permanent injunction against Rel's Foods Inc. (Rel's), of Oakland, Calif., seeking to stop the company from manufacturing, producing, and selling adulterated food products.
An innovative research agreement will put patients first in a bid to advance technology in the treatment and management of wounds - saving valuable time and money for health organisations throughout the world and helping to deliver safe and effective care.
Reuters examines how a worsening economic crisis in Greece is affecting the country's health system, highlighting a 36 percent decrease in health spending by Greeks this year, according to the National School of Public Health, and an increase of more than 50 percent in new cases of HIV from the first five months of 2010 to the same period this year.
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.
› Verified 9 days ago
Entity Name | Columbia Basin Health Association |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1528316379 PECOS PAC ID: 4486564309 Enrollment ID: O20040209000250 |
News Archive
The U.S. Department of Justice, on behalf of the U.S. Food and Drug Administration, has filed a complaint for permanent injunction against Rel's Foods Inc. (Rel's), of Oakland, Calif., seeking to stop the company from manufacturing, producing, and selling adulterated food products.
An innovative research agreement will put patients first in a bid to advance technology in the treatment and management of wounds - saving valuable time and money for health organisations throughout the world and helping to deliver safe and effective care.
Reuters examines how a worsening economic crisis in Greece is affecting the country's health system, highlighting a 36 percent decrease in health spending by Greeks this year, according to the National School of Public Health, and an increase of more than 50 percent in new cases of HIV from the first five months of 2010 to the same period this year.
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Matthew S Painter, DO 510 W 1st Ave, Toppenish, WA 98948-1564 Ph: (509) 865-5600 | Matthew S Painter, DO 510 W 1st Ave, Toppenish, WA 98948-1564 Ph: (509) 865-5600 |
News Archive
The U.S. Department of Justice, on behalf of the U.S. Food and Drug Administration, has filed a complaint for permanent injunction against Rel's Foods Inc. (Rel's), of Oakland, Calif., seeking to stop the company from manufacturing, producing, and selling adulterated food products.
An innovative research agreement will put patients first in a bid to advance technology in the treatment and management of wounds - saving valuable time and money for health organisations throughout the world and helping to deliver safe and effective care.
Reuters examines how a worsening economic crisis in Greece is affecting the country's health system, highlighting a 36 percent decrease in health spending by Greeks this year, according to the National School of Public Health, and an increase of more than 50 percent in new cases of HIV from the first five months of 2010 to the same period this year.
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.
› Verified 9 days ago
Dr. Rory C Sumners, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Buster Rd, Toppenish, WA 98948 Phone: 509-865-2102 Fax: 509-865-5374 | |
Jayme Thompson, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 510 W 1st Ave, Toppenish, WA 98948 Phone: 509-865-5600 Fax: 509-865-5783 | |
George Lupas, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 510 W 1st Ave, Toppenish, WA 98948 Phone: 509-865-5600 Fax: 509-865-5783 | |
Donn Kruse, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 401 Buster Rd, Toppenish, WA 98948 Phone: 509-865-2102 | |
Danial Hocson, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Buster Rd, Toppenish, WA 98948 Phone: 509-865-2102 | |
Sharon Dietrich, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 518 W 1st Ave, Toppenish, WA 98948 Phone: 509-865-5600 Fax: 509-865-5783 | |
Clara E Monheit, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 510 W 1st Ave, Toppenish, WA 98948 Phone: 509-865-5600 Fax: 509-865-5783 |